For the intended subcutaneous route of administration, the pharmacokinetics of glepaglutide is primarily determined by the slow release of the two main glepaglutide metabolites from a subcutaneous depot. The parent drug contributed to less than 1% of exposure at steady state.

The pharmacokinetic profile of glepaglutide is significantly protracted following subcutaneous dosing, with an estimated half-life of several days. The results support that once-weekly subcutaneous dosing of glepaglutide could be an efficacious therapy for intestinal rehabilitation in patients with short bowel syndrome.